Beyond Opioids: The Race For New Painkillers
Vertex Pharmaceuticals has halted the development of its non-opioid painkiller, creating uncertainty but also a potential opening for competitors. This theme focuses on other pharmaceutical companies that could capture market share as they advance their own non-opioid treatments.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
Vertex Pharmaceuticals' recent halt of its non-opioid painkiller development has created a significant opportunity in the pain management sector. This setback highlights the immense challenge of developing effective alternatives to traditional opioids, but also opens the door for competitors with promising treatments in their pipelines.
What You Need to Know
These are high-risk, high-reward biotech investments where clinical trial outcomes can dramatically impact valuations. The companies operate in a sector with enormous potential rewards for successful non-opioid pain treatments, but significant risks as drug development can fail at any stage.
Why These Stocks
Each company has been carefully selected for their active involvement in developing novel analgesic treatments. With one major competitor stepping back, these firms are positioned to potentially capture market share in the race to deliver the next generation of pain relief solutions.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+543.46%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 543.46% over the next year.
Stocks Rated Buy by Analysts
11 of 12 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 8.4% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
First-Mover Advantage Opportunity
With Vertex stepping back, these companies could be the first to crack the code on effective non-opioid painkillers. The company that succeeds could dominate a massive market worth billions.
Solving a Global Crisis
The opioid epidemic has created urgent demand for safer pain management alternatives. These biotech firms are racing to develop treatments that could transform healthcare and save lives.
High-Stakes Innovation
Clinical trial results in this sector can send stock prices soaring or plummeting overnight. Each company represents a calculated bet on breakthrough medical innovation with potentially massive rewards.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Unlock all the stocks in this group on Nemo
Sign up free to view all stocks in this group and never miss out on another investment opportunity with Nemo.
Sign up in 60 seconds
Zero commission trading
SIPC-protected up to $500,000
Backed by Exinity Group
6% AER interest on uninvested cash, paid out daily
AI investment insights
Discover More Opportunities
Beyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Navigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Aerospace Rivals In Focus Amid Labor Unrest
A significant strike by Boeing's defense workers in St. Louis is set to disrupt the production of crucial military aircraft. This development could create a strategic advantage for competing aerospace and defense firms poised to capture market share.
Frequently Asked Questions
Everything you need to know about the product and billing.